What is the optimal management for a patient diagnosed with asthma who has eosinophilia?

Optimal Management of Asthma with Eosinophilia

For patients with asthma and elevated eosinophils, initiate high-dose inhaled corticosteroids (ICS) combined with long-acting β2-agonists (LABA) as first-line therapy, and if control remains suboptimal despite optimal inhaled therapy, add mepolizumab (an anti-IL-5 biologic) for patients with blood eosinophils ≥150 cells/μL and recurrent exacerbations.

Initial Assessment and Baseline Treatment

Start by confirming the asthma diagnosis and quantifying eosinophilia through:

• Blood eosinophil count (≥150-300 cells/μL indicates eosinophilic phenotype) 1
• Spirometry with bronchodilator response
• Assessment of exacerbation frequency and oral corticosteroid (OCS) requirements

Begin with high-dose ICS plus LABA as the foundation 2, 3. This combination addresses both bronchodilation and airway inflammation. Optimize this regimen for at least 8-12 weeks before escalating therapy 2.

Common Pitfall to Avoid

Do not immediately jump to systemic corticosteroids or biologics without first maximizing inhaled therapy. Many patients are undertreated with suboptimal ICS doses or have poor adherence that mimics treatment failure 4.

When to Escalate: Adding Biologic Therapy

Escalate to biologic therapy when patients meet these criteria:

• Persistent symptoms despite high-dose ICS/LABA
• Blood eosinophils ≥150 cells/μL 5
• ≥2 exacerbations per year requiring systemic corticosteroids
• Impaired quality of life despite optimal inhaled therapy

Choosing the Right Biologic

For eosinophilic asthma (eosinophils ≥150 cells/μL):

1. Mepolizumab (anti-IL-5) - First choice for most patients 6, 5

   • Dose: 100 mg subcutaneously every 4 weeks
   • Particularly effective when eosinophils ≥260 cells/μL
   • Reduces exacerbations by approximately 50% and allows OCS sparing 7

2. Benralizumab (anti-IL-5 receptor α) - Alternative anti-IL-5 option 5

   • More rapid eosinophil depletion
   • Dosing every 8 weeks after loading

3. Dupilumab (anti-IL-4/13) - Consider for:

   • Type 2 asthma regardless of eosinophil level 6, 5
   • Patients with concomitant atopic dermatitis or chronic rhinosinusitis with nasal polyps
   • Corticosteroid-dependent asthma

4. Omalizumab (anti-IgE) - Reserve for:

   • Allergy-driven asthma with elevated IgE 6
   • Women planning pregnancy (most safety data) 6
   • Consider when eosinophils ≥260 cells/μL AND FeNO ≥19.5 ppb 5

Critical Decision Point: Blood Eosinophil Thresholds

Use ≥150 cells/μL as the minimum threshold to initiate anti-IL-5 therapy 5. However, response likelihood increases with higher counts:

• ≥260 cells/μL: Enhanced response probability
• ≥300 cells/μL: Even greater benefit expected

Patients with higher baseline eosinophils and more frequent exacerbations are more likely to require biologic switching if initial therapy fails 8.

Adjunctive Therapies

Add inhaled tiotropium (long-acting muscarinic antagonist) for patients with persistent symptoms on ICS/LABA before or alongside biologics 5.

Consider chronic macrolide therapy (e.g., azithromycin) for persistently symptomatic patients on maximal therapy, regardless of phenotype 5. This reduces exacerbations through anti-inflammatory mechanisms beyond antimicrobial effects.

Managing Severe or Refractory Disease

For patients with severe symptoms or inadequate response to inhaled therapy:

1. Short course of oral corticosteroids (1-2 weeks) to gain initial control 2
2. Transition immediately to ICS to maintain remission
3. Initiate biologic therapy rather than continuing repeated OCS courses to avoid long-term steroid toxicity

If asthma remains uncontrolled on first biologic:

• Verify adherence and proper inhaler technique
• Confirm eosinophilic phenotype persists
• Consider switching to alternative biologic mechanism (e.g., from anti-IL-5 to dupilumab) 8
• Patients requiring multiple biologic switches typically have higher baseline exacerbation rates (>3 per year) and maximum eosinophil counts >600 cells/μL 8

Monitoring Response

Assess treatment response at 12 months by evaluating:

• Exacerbation rate reduction (target: <1 per year)
• OCS dose reduction or elimination
• Symptom control and quality of life improvement
• Lung function stabilization or improvement

Real-world data shows mepolizumab and benralizumab maintain efficacy through 36 months, with sustained reductions in exacerbations (from ~5.8 to ~1.2 annually) and OCS requirements (from 5.3 mg/day to 0.6 mg/day) 7.

Special Considerations

Distinguish eosinophilic asthma from other eosinophilic conditions:

• Rule out eosinophilic granulomatosis with polyangiitis (EGPA) if systemic symptoms present (vasculitis, neuropathy, cardiac involvement) 3
• Consider nonasthmatic eosinophilic bronchitis if cough predominates without bronchial hyperresponsiveness 9

For EGPA with asthma component: Mepolizumab 300 mg every 4 weeks is specifically indicated for systemic disease control, though 100 mg may suffice for isolated respiratory manifestations 3.

The Bottom Line

The management algorithm is straightforward: optimize inhaled therapy first (high-dose ICS/LABA), then add mepolizumab for patients with eosinophils ≥150 cells/μL and ongoing exacerbations. This approach reduces exacerbations, eliminates or minimizes OCS exposure, and improves quality of life in the majority of patients with eosinophilic asthma 5, 7.